Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of Its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of Its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early Stage Alzheimer's Disease, Essential for Treatment With New Drugs
由英國創新局資助併發表在《領先神經科學雜誌》上的Cognetivity的里程碑式的ADEPT研究顯示,在檢測早期阿爾茨海默病認知障礙方面具有前所未有的敏感性,阿爾茨海默病是新藥治療的關鍵
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE.1UB) ("the Company" or "Cognetivity") a leading artificial intelligence (AI) healthcare technology company is pleased to announce the peer-reviewed publication of its groundbreaking Accelerating Dementia Pathway Technologies (ADePT) Study in the journal Frontiers in Aging Neuroscience - a leading academic journal on brain aging and associated diseases. The successful project, funded by the UK government innovation agency Innovate UK, was designed to validate the efficacy of Cognetivity's Integrated Cognitive Assessment (CognICA) as a cost-effective and highly accurate tool for early detection of cognitive impairment in real-world settings.
溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年8月30日)-認知神經科學有限公司(CSE:CGN)(OTCQB:CGNSF)(FSE.1UB)(“公司”或“認知性”)一家領先的人工智慧(AI)醫療保健技術公司高興地宣佈,其突破性的加速痴呆症路徑技術(ADEPT)研究發表在《老齡神經科學前沿》雜誌上,這是一份關於大腦老化和相關疾病的領先學術期刊。這一成功的專案由英國政府創新機構Innovate UK資助,旨在驗證Cognetivity的綜合認知評估(CognICA)作為一種經濟高效且高度準確的工具在現實世界環境中早期檢測認知障礙的有效性。
In this study, conducted in collaboration with Alzheimer's Research UK and Sussex Partnership NHS Trust in England, CognICA displayed outstanding capabilities in early detection of cognitive impairment. The test demonstrated far superior performance to existing standard of care tests, showing a remarkable 93% sensitivity for Cognetivity's five minute test in detecting cognitive impairment in dementia patients. These results are particularly significant when compared to the lower average sensitivity of 73% (60% for MCI) and the far longer administration time for current standard of care tests in clinical use. This shows that CognICA's ability to reliably detect cognitive issues associated with the early stage of disease when treatment is effective can drive a massive improvement in the detection, treatment and management of disease.
在這項研究中,CognICA與英國阿爾茨海默氏症研究中心和英國秀克塞克斯夥伴關係NHS信託基金合作進行,在早期發現認知障礙方面表現出出色的能力。這項測試的表現遠遠優於現有的護理測試標準,在檢測痴呆症患者認知障礙方面,Cognetivity的五分鐘測試顯示出93%的敏感度。與73%的平均敏感度(MCI為60%)和目前臨床使用的標準護理測試的更長的給藥時間相比,這些結果尤其重要。這表明,當治療有效時,CognICA能夠可靠地發現與疾病早期相關的認知問題,這可以推動疾病的檢測、治療和管理方面的巨大改進。
Furthermore, CognICA's ease of use, speed and the fact it does not require clinician time to administer enables its wide scale deployment for routine assessment in primary care, presenting CognICA as an ideal population-wide screening tool. According to the Alzheimer's Association, more than 6 million Americans are living with Alzheimer's today, and by 2050, this number is projected to rise to nearly 13 million. However, the significant challenge remains in identifying the appropriate patients for treatment at an early stage and demonstrating the evidence of cognitive improvement in real-world settings required for CMS reimbursement.
此外,CognICA的易用性、速度和不需要臨床醫生時間進行管理的事實使其能夠廣泛部署用於初級保健的常規評估,使CognICA成為一種理想的全人群篩查工具。根據阿爾茨海默氏症協會的數據,今天有600多萬美國人患有阿爾茨海默氏症,到2050年,這一數位預計將上升到近1300萬人。然而,重大挑戰仍然是在早期階段確定適當的患者進行治療,並證明CMS報銷所需的現實世界環境中認知改善的證據。
This breakthrough comes at a pivotal moment, following recent advancements like the US and Japanese approval of Eisai's (TYO: 4523) Leqembi for the treatment of Alzheimer's disease (AD), and other disease-modifying therapies (DMTs) anticipated to achieve approval in the near future. The necessity for patients to be diagnosed at the early stage of the disease for these drugs to be effective highlights the urgent need for CognICA to be deployed at scale in primary care, as its higher sensitivity levels are especially vital for detecting patients at the right time for treatment, establishing an efficient referral pathway and giving the best clinical outcomes for patients the world over.
這一突破是在一個關鍵時刻取得的,此前美國和日本最近批准衛材(TYO:4523)Leqembi用於治療阿爾茨海默病(AD),以及預計將在不久的將來獲得批准的其他疾病修改療法(DMT)。患者必須在疾病早期被診斷,這些藥物才能有效,這突顯了在初級保健中大規模部署CognICA的迫切需要,因為它的較高靈敏度水準對於在正確的治療時間發現患者、建立有效的轉診途徑並為世界各地的患者提供最佳臨床結果尤為重要。
Already in use in clinical practice in the USA, UK and Middle East, and to monitor at-risk populations in Japan and Singapore, these results further drive the evidence for CognICA's unique ability to solve the issue of reliable early detection and monitoring at this critical time in the global battle against Alzheimer's disease.
這些結果已經在美國、英國和中東的臨床實踐中使用,並在日本和新加坡監測高危人群,這些結果進一步證明CognICA在全球抗擊阿爾茨海默病的關鍵時刻具有解決可靠的早期檢測和監測問題的獨特能力。
The full article is available here:
全文可在此處找到:
Cognetivity Neurosciences' mission is to utilize its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.
認知神經科學的使命是利用其人工智慧平臺技術來改變全球大腦健康的格局,提高向患者提供的護理質量,並減少提供者和付款人的負擔和成本,實現公司為富勒生活提供更光明心靈的願景。
-------
About Cognetivity Neurosciences
關於認知神經科學
Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Cognetivity's CognICATM uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East, with regulatory approval in other regions expected later in 2023.
Cognetivity是一家技術公司,它開發了一種認知測試平臺,用於醫療、商業和消費環境。認知性的認知ICATM使用人工智慧和機器學習技術來測試大腦大片區域的表現,以幫助檢測認知功能障礙的早期跡象。CognICA目前在美國、英國、歐洲、加拿大和中東可用於臨床,其他地區的監管部門預計將於2023年晚些時候批准。
On behalf of the Board of Directors
我謹代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
Forward-looking statements:
前瞻性陳述:
Certain statements contained in this news release, including those identified by the words "anticipate," "assume," "believe," "plan," "estimate," "expect," "intend," "may," "should" and similar expressions, to the extent they relate to the Company or its management, constitute forward-looking information or statements (collectively, the "Forward-Looking Statements"). These forward-looking statements are not historical facts and reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions, and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on a number of assumptions regarding our current and future business strategies and the environment in which we operate. We assume no responsibility to update or revise forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on our forward-looking statements.
本新聞稿中包含的某些陳述,包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及類似的表述,在與公司或其管理層有關的範圍內,構成前瞻性資訊或陳述(統稱為“前瞻性陳述”)。這些前瞻性陳述不是歷史事實,反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證,涉及難以預測的風險、不確定性和假設。此類陳述基於當前預期和各種估計、因素和假設,涉及已知和未知的風險、不確定性和其他因素。這些陳述和資訊是基於對我們當前和未來的業務戰略以及我們所處的經營環境的一些假設。除法律要求外,我們不承擔更新或修改前瞻性資訊以反映新事件或新情況的責任。告誡讀者不要過度依賴我們的前瞻性陳述。
The Canadian Securities Exchange is not responsible for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性負責。
For more information, please visit: website: or contact: info@cognetivity.com; media inquiries can be sent to pr@cognetivity.com.
如需更多資訊,請訪問:網站:或聯繫方式:info@cognetivity.com;媒體查詢可發送至pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問